Table 2.
Characteristics of the study cohorts. Data are expressed as counts (percentage) and median (interquartile range). Legend: BMI = Body Mass Index; COPD = Chronic obstructive pulmonary disease; NYHA = New York Heart Association score; SAPS 3 = Simplified acute physiology score; SOFA = Sepsis-related Organ Failure; MV = Mechanical Ventilation; NMBA = Neuromuscular blocking agents; ECMO = Extracorporeal membrane oxygenation; RRT = Renal replacement therapy.
| COVID-19 (n = 39) |
Non-COVID-19 (n = 39) |
p Value | |
|---|---|---|---|
| Age, (years) | 59 (53–65) | 52 (45–68) | 0.07 |
| Male Gender, n (%) | 29 (74) | 24 (62) | 0.33 |
| BMI | 29.4 (25–32) | 26 (23–31) | 0.06 |
| Comorbidities | |||
| COPD/Asthma, n (%) | 9 (23) | 13 (33) | 0.45 |
| Arterial hypertension, n (%) | 18 (13) | 14 (14) | 0.59 |
| Admission Serum Creatinine (mg/dL) | 1.06 (0.76–1.44) | 0.95 (0.7–1.45) | 0.37 |
| Heart failure (NYHA I-II), n (%) | 4 (10) | 3 (8) | 1.00 |
| Tobacco | 4 (10) | 9 (23) | 0.22 |
| Alcohol | 2 (5) | 1 (3) | 1.00 |
| Severity Scores | |||
| SAPS 3 | 56 (50–67) | 66 (55–78) | 0.02 |
| SOFA day 1 | 7 (4–9) | 11 (7–13) | <0.01 |
| PaO2/FiO2 24 h post MV | 141 (112–200) | 131 (105–178) | 0.11 |
| Duration therapies | |||
| Mechanical Ventilation (days) | 22 (16–29) | 9 (6–18) | <0.01 |
| Sedation (days) | 18 (11–22) | 5 (4–9) | <0.01 |
| NMBA use, n (%) | 39 (100) | 37 (95) | 0.49 |
| NMBA (days) | 12 (8.5–16) | 3 (2–7) | <0.01 |
| ECMO V-V per 7 days study, n (%) | 7 (18) | 11 (28) | 0.42 |
| RRT per 7 days study, n (%) | 2 (5) | 12 (31) | <0.01 |
| ICU stay (days) | 27 (19–32) | 25 (14–41) | 0.23 |
| ICU survival, n (%) | 21 (54) | 23 (59) | 0.82 |